Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 50, Issue 5, 2009, Pages 977-982

  de Bruijn, Peter ^a   Moghaddam Helmantel, Inge M Ghobadi ^a   de Jonge, Maja J A ^a   Meyer, Thorsten ^b   Lam, Mei Ho ^a   Verweij, Jaap ^a   Wiemer, Erik A C ^a   Loos, Walter J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b GPC Biotech AG   (Germany)

Author keywords

Human; LC MS MS; Plasma; RGB 286638; Urine; Validated

Indexed keywords

ACETONITRILE; CHLORINE DERIVATIVE; FORMIC ACID; PROTEIN KINASE INHIBITOR; RGB 286638; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CALIBRATION; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG TARGETING; ELUTION; FLOW RATE; HUMAN; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; PLASMA; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; TANDEM TRIPLE QUADRUPOLE MASS SPECTROMETRY; URINE; VALIDITY;

CALIBRATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; EDETIC ACID; FORMIC ACIDS; HUMANS; MASS SPECTROMETRY; MODELS, CHEMICAL; MODELS, STATISTICAL; PROTEIN KINASE INHIBITORS; PYRAZOLES; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TEMPERATURE; TIME FACTORS; UREA;

EID: 70349180350     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2009.06.048     Document Type: Article

References (12)

1. Malumbres M., and Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 30 (2005) 630-641
2. Sherr C.J. Cancer cell cycles. Science 274 (1996) 1672-1677
3. Malumbres M., and Barbacid M. Cell cycle kinases in cancer. Curr. Opin. Genet. Dev. 17 (2007) 60-65
4. Malumbres M., Pevarello P., Barbacid M., and Bischoff J.R. CDK inhibitors in cancer therapy: what is next?. Trends Pharmacol. Sci. 29 (2008) 16-21
5. Shapiro G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24 (2006) 1770-1783
6. Caligiuri M., Bockovich N., Oalmann C., Kaplan F., Lamphere L., Wang S., Kluge A., and Kley N. Induction of tumor regression by the broad-spectrum cyclin dependent kinase inhibitor, RGB-286638. 97th Annual Meeting of the American Association for Cancer Research (AACR). Orlando, Florida (2006)
7. Caligiuri M., Loferer H., Lamphere L., and Kley N. RGB-286638 is a novel multi-targeted protein kinase inhibitor with activity in chronic myelogenous leukemia (CML) models. 20th EORTC-NCI-AACR Symposium "Molecular Targets and Cancer Therapeutics". Geneva, Switzerland (2008)
8. Cirstea D., Hideshima T., Pozzi S., Vallet S., Ikeda H., Santo L., Loferer H., Vaghela N., Okawa Y., Perrone G., Gorgun G., Calabrese E., Nikhil C., Anderson K.C., and Raje N. RGB-286638, a novel multi-targeted small molecule inhibitor, induces multiple myeloma (MM) cell death through abrogation of CDK-dependent and independent survival mechanisms. 50th American Society of Hematology (ASH) Annual Meeting. San Francisco, California (2008)
9. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., and Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24 (2007) 1962-1973
10. Matuszewski B.K., Constanzer M.L., and Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75 (2003) 3019-3030
11. Wille S.M., and Lambert W.E. Recent developments in extraction procedures relevant to analytical toxicology. Anal. Bioanal. Chem. 388 (2007) 1381-1391
12. Benijts T., Dams R., Lambert W., and De Leenheer A. Countering matrix effects in environmental liquid chromatography-electrospray ionization tandem mass spectrometry water analysis for endocrine disrupting chemicals. J. Chromatogr. A 1029 (2004) 153-159